Semaglutide Explained: Ozempic, Wegovy, and Rybelsus

Disclosure: Dose Digest is an educational publisher. We may have a financial affiliation with some entities featured on this page. This article is educational only and is not medical advice.

The short answer: Ozempic, Wegovy and Rybelsus all contain semaglutide, a GLP-1 receptor agonist. What differs is the FDA-approved label. Ozempic injection and Rybelsus tablets are indicated for type 2 diabetes; Wegovy, as an injection or a tablet, is indicated for weight reduction and cardiovascular risk reduction, among other uses. Labels define the approved uses; clinicians decide individual care.

What is semaglutide, and why does it have several names?

Semaglutide is a GLP-1 receptor agonist. The Ozempic prescribing information describes it as a GLP-1 analogue with 94% sequence homology to human GLP-1 that binds and activates the GLP-1 receptor. The same active ingredient sits inside separately approved products, each with its own application, brand name and labeled uses.

According to Drugs@FDA, Ozempic injection was first approved Dec. 5, 2017. The Rybelsus application dates to Sept. 20, 2019, and the Wegovy tablet application to Dec. 22, 2025. The Wegovy injection and tablets share one combined prescribing information.

One wrinkle: on Jan. 30, 2026, FDA approved a supplement that, in the agency’s words, changed “the name of the product from Rybelsus (formulation R2) to Ozempic (semaglutide) tablets” (FDA approval letter). The current tablet label covers both Rybelsus and Ozempic tablets. So “Ozempic” can now mean an injection or a tablet, and the two are different products.

What is each FDA label approved for?

As of Sept. 30, 2026, the labels we reviewed list these indications:

Ozempic (injection), PI revised 05/2026; DailyMed page shows “Updated June 1, 2026.” With diet and exercise, to improve glycemic control in adults with type 2 diabetes; to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and to reduce sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Wegovy (injection), PI revised 06/2026; DailyMed page shows “Updated June 18, 2026.” With a reduced-calorie diet and physical activity: weight reduction and long-term maintenance in adults and in patients 12 and older with obesity, and in adults with overweight plus a weight-related condition; cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight; and, under accelerated approval, noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
Wegovy (tablets), same combined label. Adults only: weight reduction and maintenance, and cardiovascular risk reduction, in the populations above.
Rybelsus and Ozempic tablets, PI revised 1/2026; DailyMed page shows “Updated January 30, 2026.” Glycemic control in adults with type 2 diabetes, and cardiovascular risk reduction in adults with type 2 diabetes at high risk for those events.

Is an oral Wegovy FDA-approved?

As of Sept. 30, 2026, yes. Here is what we verified on that date:

Drugs@FDA for NDA 218316 lists Wegovy tablets with an original approval action dated 12/22/2025 and a prescription marketing status. Its most recent label entry is dated 06/18/2026.
The FDA approval letter for NDA 218316, signed Dec. 22, 2025, approves Wegovy tablets for cardiovascular risk reduction and for weight reduction and long-term maintenance.
The current Wegovy PI, revised 06/2026, covers the tablets alongside the injection.

We did not verify retail availability, supply or price; those are outside the label and this page.

How do Ozempic and Wegovy differ on the label?

Both injections are once-weekly semaglutide products, but the labels diverge in purpose. Ozempic’s label centers on type 2 diabetes: glycemic control plus cardiovascular and kidney outcomes in people with diabetes. Wegovy’s centers on weight reduction and maintenance, cardiovascular risk reduction in adults with established disease plus obesity or overweight, a liver indication, and an adolescent weight indication. The labels describe different step-up structures, and trial populations differ too, so figures from one label should not be read against another.

What do the labels say about dosing, in plain terms?

This section describes label structure only. Your clinician determines what applies to you.

Every label describes a gradual increase in stages at set intervals.
Injections are labeled for once-weekly use; tablets for once-daily use.
The Wegovy label says that if a step is not tolerated, delaying escalation can be considered.
Staging and maintenance vary by product, and the tablet and injection structures differ.
Missed-dose language differs between weekly injections and daily tablets, so a label summary is not a substitute for your prescriber’s guidance.
The tablet labels describe taking the tablet once daily on an empty stomach with a small amount of water, then waiting before eating.
The tablet label says Rybelsus and Ozempic tablets are not interchangeable milligram for milligram. Moving between products is a prescriber decision.

What did the trials report?

These figures come from the labels, are from trials, and are not head-to-head comparisons.

Ozempic, cardiovascular outcomes: In SUSTAIN 6 (NCT01720446), 3,297 adults with type 2 diabetes at high cardiovascular risk, most with established cardiovascular disease, were followed for a median of 2.1 years. The composite of cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.6% (108 of 1,648) on Ozempic versus 8.9% (146 of 1,649) on placebo; hazard ratio 0.74 (95% CI 0.58 to 0.95) (PI).
Wegovy, cardiovascular outcomes: In the label’s Study 1 (NCT03574597), 17,604 adults aged 45 or older with established cardiovascular disease and overweight or obesity, without diabetes, were followed for a median of 41.8 months. The same composite occurred in 6.5% (569 of 8,803) on Wegovy versus 8% (701 of 8,801) on placebo; hazard ratio 0.80 (95% CI 0.72 to 0.90). (PI).
Rybelsus, cardiovascular outcomes: In Trial 7 (NCT03914326), 9,650 adults with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease were followed for a median of about 49.6 months. The composite occurred in 12% (579 of 4,825) on the tablet versus 13.8% (668 of 4,825) on placebo; hazard ratio 0.86 (95% CI 0.77 to 0.96) (PI).

What warnings and side effects do the labels share?

All semaglutide labels carry a boxed warning about thyroid C-cell tumors. In rodents, semaglutide caused them; whether it does in humans has not been determined. The labels contraindicate use with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, among other contraindications, including serious hypersensitivity to the drug. Other warnings include pancreatitis, gallbladder disease, acute kidney injury from dehydration, severe gastrointestinal reactions, hypersensitivity reactions, and pulmonary aspiration during general anesthesia or deep sedation. All three labels also flag diabetic retinopathy complications, and hypoglycemia when used with insulin or an insulin secretagogue (such as a sulfonylurea).

Trial-reported gastrointestinal rates, per the labels:

Wegovy injection (weight-reduction trials, 2,116 adults, up to 68 weeks): nausea 44% versus 16%; diarrhea 30% versus 16%; vomiting 24% versus 6%; constipation 24% versus 11%.
Ozempic (placebo-controlled type 2 diabetes pool, 521 treated, mean exposure 32.9 weeks): nausea about 16% to 20% across treatment arms versus 6.1% on placebo.
Wegovy tablets (204 adults, up to 64 weeks): severe gastrointestinal reactions 2% versus 0% on placebo.

What about compounded semaglutide?

Compounded semaglutide is not FDA-approved, as FDA states.

Questions a reader might bring to their own clinician

Which labeled indication matches my situation, and is this product used within it?
Which form (injection or tablet) does my clinician have in mind, and what differs on its label?
What warnings apply given my history, including thyroid, pancreas, gallbladder, eye and kidney history?
How should I plan around surgery or anesthesia?
How will side effects be monitored during step-ups?

Frequently asked questions

Is Ozempic the same as Wegovy?

They share the active ingredient, semaglutide, but they are separate products with separate labels, indications and presentations.

Is Rybelsus the same as oral Wegovy?

No. They are under different applications (NDA 213051 and NDA 218316) with different indications, per Drugs@FDA.

Is there an FDA-approved oral Wegovy?

Yes, as of Sept. 30, 2026, per Drugs@FDA and the FDA approval letter dated Dec. 22, 2025.

Does Ozempic’s label include weight management?

No. The Ozempic injection indications cover type 2 diabetes outcomes. Individual treatment decisions are for a clinician.

Can semaglutide products be combined?

The Wegovy label’s limitations of use say concomitant use with other semaglutide-containing products, or any other GLP-1 receptor agonist, is not recommended.